Filing Flows › Comparisons › UPB vs OVID
Upstream Bio vs Ovid Therapeutics: UPB and OVID compared
Upstream Bio is the larger company: $773K of revenue in its latest quarter (Q2 2026) against $733K for Ovid Therapeutics (Q2 2026). Upstream Bio is growing faster (-18% against -88% a year earlier).
Where the money goes: UPB and OVID
Upstream Bio (UPB) · Q2 2026
Upstream Bio, Q2 2026: revenue $773K (-18% year over year), net loss $39.7M, operating cash flow −$35.6M. The chart follows the revenue to costs, profit and cash.
Ovid Therapeutics (OVID) · Q2 2026
Ovid Therapeutics, Q2 2026: revenue $733K (-88% year over year), net loss $15.0M, operating cash flow −$17.6M. The chart follows the revenue to costs, profit and cash.
| Upstream Bio (UPB) | Ovid Therapeutics (OVID) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $773K | $733K |
| Revenue growth, Y/Y | -18% | -88% |
| Operating margin | n/m | n/m |
| Net earnings | −$39.7M | −$15.0M |
| Operating cash flow | −$35.6M | −$17.6M |
Questions
Which is bigger, Upstream Bio or Ovid Therapeutics?
Upstream Bio is the larger company: $773K of revenue in its latest quarter (Q2 2026) against $733K for Ovid Therapeutics (Q2 2026).
Is Upstream Bio or Ovid Therapeutics growing faster?
Upstream Bio is growing faster (-18% against -88% a year earlier).
More: Upstream Bio earnings · how Upstream Bio makes money · Ovid Therapeutics earnings · how Ovid Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.